Lilly data show lower-dose GLP-1 injections and oral pill help sustain weight loss

Eli Lilly presented new research on how patients who have lost weight with GLP‑1 medicines can maintain that loss over time. The studies followed people who had achieved significant reductions using Lilly’s injectable Zepbound or Novo Nordisk’s Wegovy and then continued treatment at a lower injection dose or switched to the newly launched oral pill Foundayo.

Two year‑long trials – Surmount‑Maintain published in The Lancet and Attain‑Maintain in Nature Medicine – compared the maintenance strategies with placebo. Both approaches produced statistically significant weight‑loss maintenance, outperforming the control group.

The findings were timed with Lilly’s presentation at a European obesity conference, highlighting a potential pathway to address the common challenge of weight‑regain after initial GLP‑1 therapy. Investors and clinicians see the data as a promising step toward broader, longer‑term obesity management options.